There are 2867 resources available
712P - CAPT: A multicenter randomized controlled trial of perioperative versus postoperative camrelizumab plus apatinib for resectable hepatocellular carcinoma
Presenter: Xueli Bai
Session: Poster session 13
713P - Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240
Presenter: Julien Edeline
Session: Poster session 13
714P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Lam Chan
Session: Poster session 13
715P - The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: Interim results from a multicenter prospective cohort study
Presenter: zhang xiaoyun
Session: Poster session 13
716P - Impact of COVID-19 pandemic on clinical outcomes in hepatocellular carcinoma: A multicentre cohort study
Presenter: Shuell De Souza
Session: Poster session 13
717P - Phase II study of transhepatic artery chemoembolization (TACE) combined with tislelizumab (TIS) and lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma(uHCC)
Presenter: Xiang Nong
Session: Poster session 13
718P - Prognosis-related molecular subtypes and immune features associated with hepatocellular carcinoma
Presenter: Jiazhou Ye
Session: Poster session 13
720P - Integrative genomic analysis of matched primary and recurrent tumors reveals molecular characteristics of hepatocellular carcinoma with short-term recurrence
Presenter: Jingyu Cao
Session: Poster session 13
721P - Molecular alterations as predictors of response to immunotherapy in hepatocellular carcinoma
Presenter: Jeremy Chang
Session: Poster session 13